These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 24721226)

  • 41. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.
    Evans EK; Tester R; Aslanian S; Karp R; Sheets M; Labenski MT; Witowski SR; Lounsbury H; Chaturvedi P; Mazdiyasni H; Zhu Z; Nacht M; Freed MI; Petter RC; Dubrovskiy A; Singh J; Westlin WF
    J Pharmacol Exp Ther; 2013 Aug; 346(2):219-28. PubMed ID: 23709115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.
    Mohamed AJ; Yu L; Bäckesjö CM; Vargas L; Faryal R; Aints A; Christensson B; Berglöf A; Vihinen M; Nore BF; Smith CI
    Immunol Rev; 2009 Mar; 228(1):58-73. PubMed ID: 19290921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective.
    Satterthwaite AB; Witte ON
    Immunol Rev; 2000 Jun; 175():120-7. PubMed ID: 10933597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bruton's tyrosine kinase (Btk)-the critical tyrosine kinase in LPS signalling?
    Jefferies CA; O'Neill LA
    Immunol Lett; 2004 Mar; 92(1-2):15-22. PubMed ID: 15081522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.
    Smith CI; Baskin B; Humire-Greiff P; Zhou JN; Olsson PG; Maniar HS; Kjellén P; Lambris JD; Christensson B; Hammarström L
    J Immunol; 1994 Jan; 152(2):557-65. PubMed ID: 8283037
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
    Honigberg LA; Smith AM; Sirisawad M; Verner E; Loury D; Chang B; Li S; Pan Z; Thamm DH; Miller RA; Buggy JJ
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13075-80. PubMed ID: 20615965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Btk inhibition treats TLR7/IFN driven murine lupus.
    Bender AT; Pereira A; Fu K; Samy E; Wu Y; Liu-Bujalski L; Caldwell R; Chen YY; Tian H; Morandi F; Head J; Koehler U; Genest M; Okitsu SL; Xu D; Grenningloh R
    Clin Immunol; 2016 Mar; 164():65-77. PubMed ID: 26821304
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lysine acetylation regulates Bruton's tyrosine kinase in B cell activation.
    Liu Z; Mai A; Sun J
    J Immunol; 2010 Jan; 184(1):244-54. PubMed ID: 19949111
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functions of Bruton's tyrosine kinase in mast and B cells.
    Kawakami Y; Kitaura J; Hata D; Yao L; Kawakami T
    J Leukoc Biol; 1999 Mar; 65(3):286-90. PubMed ID: 10080529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bruton's tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin.
    Byrne JC; Ní Gabhann J; Stacey KB; Coffey BM; McCarthy E; Thomas W; Jefferies CA
    J Immunol; 2013 May; 190(10):5207-15. PubMed ID: 23596312
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of protein kinase CbetaI by two protein-tyrosine kinases, Btk and Syk.
    Kawakami Y; Kitaura J; Hartman SE; Lowell CA; Siraganian RP; Kawakami T
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7423-8. PubMed ID: 10852954
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
    Norman P
    Expert Opin Investig Drugs; 2016 Aug; 25(8):891-9. PubMed ID: 27148767
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The protein defective in X-linked agammaglobulinemia, Bruton's tyrosine kinase, shows increased autophosphorylation activity in vitro when isolated from cells in which the B cell receptor has been cross-linked.
    Hinshelwood S; Lovering RC; Genevier HC; Levinsky RJ; Kinnon C
    Eur J Immunol; 1995 Apr; 25(4):1113-6. PubMed ID: 7737282
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tec family kinases in inflammation and disease.
    Horwood NJ; Urbaniak AM; Danks L
    Int Rev Immunol; 2012 Apr; 31(2):87-103. PubMed ID: 22449071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model.
    Wu H; Huang Q; Qi Z; Chen Y; Wang A; Chen C; Liang Q; Wang J; Chen W; Dong J; Yu K; Hu C; Wang W; Liu X; Deng Y; Wang L; Wang B; Li X; Gray NS; Liu J; Wei W; Liu Q
    Sci Rep; 2017 Mar; 7(1):466. PubMed ID: 28352114
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.
    Lindvall JM; Blomberg KE; Väliaho J; Vargas L; Heinonen JE; Berglöf A; Mohamed AJ; Nore BF; Vihinen M; Smith CI
    Immunol Rev; 2005 Feb; 203():200-15. PubMed ID: 15661031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
    Shi Q; Tebben A; Dyckman AJ; Li H; Liu C; Lin J; Spergel S; Burke JR; McIntyre KW; Olini GC; Strnad J; Surti N; Muckelbauer JK; Chang C; An Y; Cheng L; Ruan Q; Leftheris K; Carter PH; Tino J; De Lucca GV
    Bioorg Med Chem Lett; 2014 May; 24(9):2206-11. PubMed ID: 24685542
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease.
    Corneth OBJ; Verstappen GMP; Paulissen SMJ; de Bruijn MJW; Rip J; Lukkes M; van Hamburg JP; Lubberts E; Bootsma H; Kroese FGM; Hendriks RW
    Arthritis Rheumatol; 2017 Jun; 69(6):1313-1324. PubMed ID: 28141917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers.
    Watterson SH; De Lucca GV; Shi Q; Langevine CM; Liu Q; Batt DG; Beaudoin Bertrand M; Gong H; Dai J; Yip S; Li P; Sun D; Wu DR; Wang C; Zhang Y; Traeger SC; Pattoli MA; Skala S; Cheng L; Obermeier MT; Vickery R; Discenza LN; D'Arienzo CJ; Zhang Y; Heimrich E; Gillooly KM; Taylor TL; Pulicicchio C; McIntyre KW; Galella MA; Tebben AJ; Muckelbauer JK; Chang C; Rampulla R; Mathur A; Salter-Cid L; Barrish JC; Carter PH; Fura A; Burke JR; Tino JA
    J Med Chem; 2016 Oct; 59(19):9173-9200. PubMed ID: 27583770
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.